How XELJANZ Works. XELJANZ is a Janus kinase (JAK) inhibitor that helps regulate an overactive immune system. It helps disrupt JAK pathways from inside the cells, which are believed to play a role in inflammation.

People taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily have a higher risk of certain cancers including lymphoma and lung cancer, especially if you are a current or past smoker. Tell your healthcare provider if you have ever had any type of cancer.

How XELJANZ Works. XELJANZ is a Janus kinase (JAK) inhibitor that helps regulate an overactive immune system. It helps disrupt JAK pathways from inside the cells, which are believed to play a role in inflammation. XELJANZ helps reduce inflammation, a cause of permanent joint damage.

Rx XELJANZ is for adults with active ankylosing spondylitis (AS) when tumor necrosis factor (TNF) blockers did not work well or could not be tolerated. Explore A Different Way To Treat Adults With Active Ankylosing Spondylitis (AS)

Are you starting on treatment with XELJANZ, but concerned about covering the cost? You may be eligible for the XELJANZ Co-Pay Savings Program for commercially insured patients or qualify for other financial support resources to help access your treatment.

See XELJANZ® (tofacitinib) risks & benefits. Sign up for information, lifestyle tips, and tools for different steps of your treatment plan.

Whether you want to learn more about XELJANZ or have already started on treatment, we can provide you with tools, resources, and support.

Learn about your treatment, including milestones, possible results and your new daily routine while taking XELJANZ and how it may help your RA symptoms.

XELJANZ can be filled by both retail and specialty pharmacies. Your insurance provider and plan often determine where your prescription gets filled and your cost.

What is XELJANZ/ XELJANZ XR/ XELJANZ Oral Solution? XELJANZ/ XELJANZ XR (tofacitinib) is used to treat adults with: Moderately to severely active rheumatoid arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or cannot be tolerated